Age-Related Macular Degeneration (AMD) Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

Age-Related Macular Degeneration (AMD) Market Trends & Summary

Age-Related Macular Degeneration (AMD) Market is expected to reach US$ 20.88 billion by 2033 from US$ 11.42 billion in 2024, with a CAGR of 6.94% from 2025 to 2033. The aging population, rising rates of lifestyle-related risk factors, improved diagnostic tools, more awareness, and the creation of novel AMD treatments and therapies are the main factors propelling the Age-Related Macular Degeneration (AMD) market.

The report Age-Related Macular Degeneration (AMD) Global Market & Forecast covers by Disease Type (Dry Age-Related Macular Degeneration Market, Wet Age-Related Macular Degeneration Market) Product (Eylea, Lucentis, Beovu, Others) Distribution Channel (Hospital Pharmacy, Specialty Pharma, Online Pharmacy) Countries and Company Analysis, 2025-2033.

Global Age-Related Macular Degeneration (AMD) Industry Overview

In affluent societies, age-related macular degeneration (AMD) is the primary cause of blindness in older adults. It is an age-related eye condition that gradually impairs the central vision required for reading, driving, facial recognition, and color vision. As AMD worsens, central vision is lost, impairing quality of life by preventing many patients from reading, writing, or recognizing color and detail. Recent advancements in genetic technologies have led to the discovery of several variants that have been demonstrated to have distinct relationships with AMD, despite the fact that the precise functional pathophysiology of AMD is still unclear.

The macula, the core portion of the retina, gradually degenerates in age-related macular degeneration, resulting in central vision loss. Based on its clinical characteristics, such as drusen, aberrant pigmentation, atrophy of the retinal pigment epithelium (RPE), and exudative choroidal neovascularization (CNV), age-related macular degeneration can be categorized as early, intermediate, or late. Another way to describe age-related macular degeneration is as wet (exudative or neovascular) or dry (atrophic or non-neovascular).

The market is expected to be primarily driven by the introduction of new products, a robust product pipeline, and an increase in the prevalence of AMD. According to the Population Reference Bureau, the number of Americans 65 and older is expected to increase by 47%, from 58 million in 2022 to 82 million in 2050. Today, the U.S. population is older than it has ever been.

One of the main elements driving category expansion is the aging population. About 200,000 new cases of wet AMD are discovered in North America each year, according to Genentech. Wet AMD causes 90 percent of legal blindness but only accounts for about 10 percent of events. Because of the unchecked proliferation of new blood vessels in the eye, which results in fluid leaking into the macula, this advanced variety can cause rapid and severe vision loss.

Growth Drivers for the Age-Related Macular Degeneration (AMD) Market

Innovative Treatment Options

The management of age-related macular degeneration (AMD) has changed dramatically as a result of the introduction of novel medications, including as anti-VEGF (vascular endothelial growth factor) therapy. These therapies have been shown to stabilize or enhance vision in a large number of patients by preventing aberrant blood vessel formation in the retina, which is a defining feature of wet AMD. Furthermore, by focusing on the genetic defects that cause AMD, advances in gene therapy hold the promise of treating the disease's underlying causes. The market is expanding as a result of these new treatment options, which can delay the course of AMD and enhance patients' quality of life. It is anticipated that more ground-breaking treatments will surface as research progresses, increasing the range of available treatments and improving patient outcomes.

Increasing Awareness

Growing public knowledge of age-related macular degeneration (AMD) is a major factor in the market's growth. The public is being educated about the symptoms, risk factors, and significance of early diagnosis through awareness programs run by patient advocacy organizations, healthcare organizations, and ophthalmology experts. People are more inclined to seek early screening as they become more knowledgeable about the illness, which can result in earlier therapies that can improve outcomes. More people are identifying AMD in its early stages thanks to better access to healthcare, especially in poorer nations. The market for AMD is developing as a result of increased awareness and proactive healthcare strategies, which are driving up demand for diagnostic and treatment solutions.

Rising Healthcare Investments

New and better treatments for Age-Related Macular Degeneration (AMD) are being developed more quickly thanks to increased funding for ophthalmology and retinal research. More research into improved diagnostic methods, cutting-edge treatments, and even cures for AMD is being made possible by increased funding from the public and commercial sectors. Additionally, this investment is supporting clinical trials for potential medications and therapies that could provide better treatments for both wet and dry forms of AMD. The market for AMD is seeing the introduction of innovative treatments and diagnostic tools due to technological breakthroughs and an increasing emphasis on retinal health. These developments will ultimately improve patient care and propel market expansion.

Challenges in the Age-Related Macular Degeneration (AMD) Market

High Treatment Costs

Patients may need repeated injections over long periods of time, and treatments for Age-Related Macular Degeneration (AMD), particularly anti-VEGF medications, can be costly. Both patients and healthcare systems may experience severe financial hardship as a result of these exorbitant expenses, especially in areas with low and moderate incomes where access to cutting-edge treatments may be restricted. Many patients may decide not to seek or continue treatment because of the cost of the drugs, as well as the requirement for frequent monitoring and follow-up appointments. The problem could be made worse by the possibility that insurance coverage won't completely cover the expenses. Many people with untreated or inadequately treated AMD are unable to receive prompt care because to financial constraints, which eventually lowers their quality of life and raises long-term healthcare expenditures.

Lack of Early Diagnosis

In its early stages, patients may not detect any signs of age-related macular degeneration (AMD), which frequently develops slowly. Because of this, many people wait until they have experienced severe vision loss before seeking medical help. Early detection can be difficult due to the disease's sluggish progression, and by the time patients receive a diagnosis, the illness is frequently well advanced. Since early intervention is essential to maintaining eyesight and halting progressive degeneration, this diagnosis delay lessens the efficacy of the treatments that are now available. Many cases of AMD remain misdiagnosed due to a lack of routine screenings, especially for at-risk populations. This leads to avoidable vision loss and poor treatment outcomes.

United States Age-Related Macular Degeneration (AMD) Market

The aging population and greater awareness of eye health are driving the rapid growth of the Age-Related Macular Degeneration (AMD) market in the United States. As the U.S. population ages, AMD, which mostly affects people over 60, is growing more common. The availability of efficient treatments, including as anti-VEGF medications, which have greatly improved patient outcomes, especially for wet AMD, and improvements in diagnostic technologies are driving the market. Nonetheless, issues like exorbitant treatment expenses and the scarcity of treatments for dry AMD continue to exist. Furthermore, the market is impacted by elements like the availability of healthcare, reimbursement regulations, and the growing need for specialized eye care. With continued research and the launch of novel treatments, the AMD industry in the US is still expanding in spite of these obstacles.

Germany Age-Related Macular Degeneration (AMD) Market

The aging population and growing awareness of eye health are driving the growth of the Age-Related Macular Degeneration (AMD) market in Germany. The prevalence of AMD, especially wet AMD, is increasing as a large percentage of the population ages over 60. With its sophisticated diagnostic equipment and treatment choices, including anti-VEGF medications, which have significantly improved eyesight outcomes, Germany boasts a strong healthcare system. For dry AMD, there are still a number of obstacles to overcome, including as the high expense of therapy and the scarcity of available solutions. Regionally specific reimbursement policies and regulatory frameworks can have an impact on the market. Despite these obstacles, Germany remains one of Europe's top markets for AMD treatment, with an increasing emphasis on patient access to care, technical advancements, and research.

India Age-Related Macular Degeneration (AMD) Market

India's rapidly aging population and rising awareness of eye health are driving the country's Age-Related Macular Degeneration (AMD) market. The prevalence of AMD is increasing, particularly in urban regions, due to a large older population. But access to cutting-edge diagnostic equipment and therapies is still restricted, especially in rural areas. The main treatment for wet AMD is now anti-VEGF medicines; nevertheless, market expansion is hampered by high costs and a lack of a widely available healthcare infrastructure. Furthermore, although more people are aware of the problem, many individuals wait until they have suffered severe visual loss before seeking medical attention. Notwithstanding these obstacles, the need for reasonably priced therapies is rising, and the Indian government's efforts to increase access to healthcare are probably going to help the AMD market grow over the next several years.

Saudi Arabia Age-Related Macular Degeneration (AMD) Market

The rising incidence of age-related eye disorders in the elderly population is driving growth in the Age-Related Macular Degeneration (AMD) market in Saudi Arabia. More people are seeking early diagnosis and treatment for AMD as a result of an improved healthcare system and increased knowledge of eye health. In large cities, anti-VEGF treatments are becoming more widely available, especially for wet AMD. Nonetheless, issues like exorbitant medical expenses and restricted access to cutting-edge healthcare in rural regions continue to exist. The demand for specialist ophthalmic care and diagnostic technology also affects the industry. Despite these obstacles, the AMD market is anticipated to increase in the region due to Saudi Arabia's emphasis on enhancing healthcare infrastructure, government efforts, and a rising desire for improved healthcare access.

Age-Related Macular Degeneration (AMD) Market Segments

Disease Type-Market breakup in 2 viewpoints:

1. Dry Age-Related Macular Degeneration Market

2. Wet Age-Related Macular Degeneration Market

Product - Market breakup in 4 viewpoints:

1. Eylea

2. Lucentis

3. Beovu

4. Others

Distribution Channel - Market breakup in 3 viewpoints:

1. Hospital Pharmacy

2. Specialty Pharma

3. Online Pharmacy

Country

North America

1. United States

2. Canada

Europe

1. France

2. Germany

3. Italy

4. Spain

5. United Kingdom

6. Belgium

7. Netherlands

8. Turkey

Asia Pacific

1. China

2. Japan

3. India

4. Australia

5. South Korea

6. Thailand

7. Malaysia

8. Indonesia

9. New Zealand

Latin America

1. Brazil

2. Mexico

3. Argentina

Middle East & Africa

1. South Africa

2. Saudi Arabia

3. UAE

All the Key players have been covered from 4 Viewpoints:

• Overview
• Key Persons
• Recent Development & Strategies
• Financial Insights
• Company Analysis:

1. Hoffmann - La Roche Ltd.

2. Bayer AG

3. Abbvie

4. GSK Plc

5. Novartis AG

6. Regeneron Pharmaceuticals

7. Bausch Health Companies Inc.

8. Alimera Sciences Inc.